Targeting IL‐13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL‐13‐PE and gemcitabine-Reference-Cited by-同舟云学术

Targeting IL‐13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL‐13‐PE and gemcitabine

Published:2010-05-05 Issue:5 Volume:128 Page:1221-1231
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Fujisawa Toshio¹,Nakashima Hideyuki¹,Nakajima Atsushi²,Joshi Bharat H.¹,Puri Raj K.¹

Affiliation:

1. Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD

2. Gastroenterology Division, Yokohama City University, Graduate School of Medicine, Yokohama, Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.25437

Reference38 articles.

1. Cancer of the Pancreas: Are we Making Progress? A Review of Studies in the US Oncology Research Network

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

4. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

5. Interleukin‐13 receptor alpha chain: a novel tumor‐associated transmembrane protein in primary explants of human malignant gliomas;Joshi BH;Cancer Res,2000

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The oncofetal protein IMP1 regulates the transcriptomic landscape to drive early events in pancreatic cancer progression and growth;2024-07-02

2. CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens;Biology;2023-02-10

3. Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy;Pancreas;2022-10

4. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy;Frontiers in Immunology;2022-04-08

5. Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer;International Journal of Molecular Sciences;2021-03-15